DOST to fund clinical trials for lagundi as Covid-19 therapeutic
The Department of Science and Technology has approved funding for clinical trials of lagundi as an “adjuvant therapeutic” for Covid-19 patients.
The Department of Science and Technology has approved funding for clinical trials of lagundi as an “adjuvant therapeutic” for Covid-19 patients.
The Inter-Agency Task Force for the Management of Emerging Infectious Diseases on May 22 approved the country’s participation in clinical trials for Covid-19 vaccines, in collaboration with four Asian organizations.